-
2022-502779-40-99
5
Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
-
2024-518821-13-00
4
Non-cystic Fibrosis Bronchiectasis
-
2025-520554-11-00
5
Cardiovascular Disease
-
2025-520587-18-00
4
Focal Onset Seizures
-
2025-521985-82-00
4
Diabetic sensorimotor polyneuropathy (DSPN)
-
2025-522552-20-00
5
2026-05-28
Lennox-Gastaut Syndrome
-
2024-519870-38-00
5
2026-05-11
Atherosclerotic cardiovascular disease (ASCVD)
-
2025-524498-17-00
10
2026-05-08
Pretreated Unresectable Locally Advanced or Metastatic human epidermal
-
2024-515445-42-00
5
2025-03-24
Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
-
2024-514499-42-00
5
2025-03-12
Refractory Partial Onset Epilepsy
-
2023-504231-41-01
4
2024-10-02
Locally advanced or metastatic urothelial cancer
-
2023-504918-29-00
5
2024-08-22
Hormone receptor positive breast cancer
-
2023-504214-30-00
5
2024-06-27
Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
-
2023-503545-67-00
5
2024-04-30
Tourette's Disorder
-
2022-501099-24-00
5
2023-12-22
Migraine
-
2022-501100-94-00
5
2023-11-08
Episodic Migraine
-
2022-500544-38-00
5
2023-06-05
Advanced Breast Cancer
-
2025-522542-40-00
5
2026-06-19
Acute Ischemic Stroke
-
2024-514874-36-01
4
2026-04-17
Refractory angina due to obstructive coronary artery disease
-
2024-520101-39-00
5
2026-04-01
TROP2 NMR-positive advanced or metastatic non-squamous non-small cell
-
2025-521636-10-00
4
2026-02-04
Progressive Forms of Multiple Sclerosis (PMS)
-
2024-516652-18-00
5
2025-10-10
Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
-
2025-520519-14-00
5
2025-09-03
Atherosclerotic Cardiovascular Disease
-
2024-512583-57-00
5
2025-07-30
HER2-positive locally advanced or metastatic gastric or gastroesophage